Labo EuromedisXPAR:ALEMG 61 Gross Margin % is -6.33% as of Dec. 2025. GuruFocus rates XPAR:ALEMG with a GF Score™ of 61/100 and a GF Value™ of €4.48 (Fairly Valued). The stock has 6 warning signs investors should review. Among 116 Medical Distribution companies, Labo Euromedis ranks worse than 66.38% on this metric.
Labo Euromedis gross margin has been in long-term decline. The average rate of decline per year is -34.7%.
The historical rank and industry rank for Labo Euromedis's Gross Margin % or its related term are showing as below:
XPAR:ALEMG'
s Gross Margin % Range Over the Past 10 Years
Min: 0.53 Med: 32.72 Max: 41.46
Current: 10.79
During the past 13 years, the highestGross Margin % of Labo Euromedis was 41.46%. The lowest was 0.53%. And the median was 32.72%.
XPAR:ALEMG's Gross Margin % is ranked worse than 66.38% of 116
companies
in the Medical Distribution industry
Industry Median: 14.9
vs XPAR:ALEMG: 10.79
Labo Euromedis had a gross margin of -6.33% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Labo Euromedis was -34.70% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Labo Euromedis had a gross margin of -6.33% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Labo Euromedis Gross Margin % Related Terms
Labo Euromedis Gross Margin % Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALEMG vs MCK, CAH, COR: Gross Margin % Comparison
For the Medical Distribution subindustry, Labo Euromedis's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Labo Euromedis (XPAR:ALEMG) has a Gross Margin % of -6.33% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Labo Euromedis and its competitors. Over the past decade, Labo Euromedis' Gross Margin % has ranged from 0.53 to 41.46. According to the industry distribution chart, Labo Euromedis ranks #77 out of 116 companies in the Medical Distribution industry, placing it in the top 66.4%.
Is Labo Euromedis' Gross Margin % too high?
Labo Euromedis' current Gross Margin % is -6.33%. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 41.46. Based on the distribution chart, Labo Euromedis ranks #77 out of 116 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Labo Euromedis has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Gross Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #77 out of 116 companies for Gross Margin %. This places Labo Euromedis in the lower half of its industry. The industry median Gross Margin % is 14.90. Historically, Labo Euromedis' own Gross Margin % has ranged from 0.53 to 41.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Gross Margin % is -6.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (XPAR:ALEMG) is currently considered Fairly Valued. The stock's GF Value™ is €4.48, compared to a current price of €4.88 — trading 8.9% above its estimated fair value. The current Gross Margin % is -6.33%. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Labo Euromedis (XPAR:ALEMG), the current Gross Margin % is -6.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (XPAR:ALEMG) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.88 is trading 8.9% above its estimated GF Value™ of €4.48.
GuruFocus considers Labo Euromedis to be Fairly Valued.
Key valuation signals for XPAR:ALEMG:
Gross Margin %: -6.33%
GF Value™: €4.48 vs. price of €4.88 (8.9% above fair value)
No single metric tells the full story. See the XPAR:ALEMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score
Get the complete analysis for XPAR:ALEMG
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALEMG has been successfully added to your 
